Flora Growth's EPS (Basic) for the
three
months ended in Dec. 2023 was $-0.82.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.82.
Flora Growth's EPS without NRI for the
three
months ended in Dec. 2023 was $0.01.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.24.
During the past 3 years, the average EPS without NRIGrowth Rate was 37.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 5 years, Flora Growth's highest 3-Year average EPS without NRI Growth Rate was 37.90% per year. The lowest was 37.90% per year. And the median was 37.90% per year.
Flora Growth EPS (Diluted) Historical Data
The historical data trend for Flora Growth's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Flora Growth's EPS (Diluted)
For the Drug Manufacturers - Specialty & Generic subindustry, Flora Growth's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flora Growth's PE Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Flora Growth's PE Ratio distribution charts can be found below:
* The bar in red indicates where Flora Growth's PE Ratio falls into.
Flora Growth EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Flora Growth's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.84
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flora Growth (NAS:FLGC) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Flora Growth EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of Flora Growth's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company operates in the United States, Germany, Colombia, the United Kingdom, and Canada. it derives a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FLGC has been successfully added to your 